lg121071 lg121071 lg121071 (or lgd-121071) is a selective androgen receptor modulator (sarm) developed by ligand pharmaceuticals that was first described in 1999 and was the first orally active nonsteroidal androgen to be discovered. it is a tricyclic quinolone derivative, structurally distinct from other nonsteroidal ar agonists like andarine and enobosarm (ostarine). the drug acts as a high-affinity full agonist of the androgen receptor (ar) (ki = 17 nm), with a potency and efficacy that is said to be equivalent to that of dihydrotestosterone (dht). unlike testosterone, but similarly to dht, lg121071 and other nonsteroidal androgens cannot be potentiated by 5α-reductase in androgenic tissues (nor aromatized into estrogenic metabolites), and for this reason, show tissue-selective androgenic effects. in accordance, they are said to possess full anabolic activity with reduced androgenic activity, similarly to anabolic-androgenic steroids. lg121071clinical dataother nameslg-121071; lgd-121071identifiers iupac name 6-ethyl-4-(trifluoromethyl)-1h,2h,6h,7h,8h,9h-pyridoquinolin-2-one cas number179897-70-2pubchem cid9839132chemspider8014851chemblchembl390728chemical and physical dataformulac15h15f3n2omolar mass296.293 g·mol−13d model (jsmol)interactive image smiles ccc1ccnc2=c1c=c3c(=cc(=o)nc3=c2)c(f)(f)f inchi inchi=1s/c15h15f3n2o/c1-2-8-3-4-19-12-7-13-10(5-9(8)12)11(15(16,17)18)6-14(21)20-13/h5-8,19h,2-4h2,1h3,(h,20,21)key:szppqfartyxrku-uhfffaoysa-n the in vitro metabolism of lg121071 has been characterized in anticipation of its possible use as a doping agent.